NCT02913157View on ClinicalTrials.gov

Hydroxychloroquine in Primary Progressive Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions
Multiple Sclerosis, Primary Progressive
Interventions
DRUG

Hydroxychloroquine

Orally administered Hydroxychloroquine

Trial Locations (1)

T2N2T9

MS Clinic Foothills Medical Centre, Calgary

All Listed Sponsors
lead

University of Calgary

OTHER

NCT02913157 - Hydroxychloroquine in Primary Progressive Multiple Sclerosis | Biotech Hunter | Biotech Hunter